Relay Therapeutics (RLAY) Accumulated Depreciation (2019 - 2023)

Relay Therapeutics (RLAY) has 5 years of Accumulated Depreciation data on file, last reported at $23.6 million in Q4 2023.

• Accumulated Depreciation for Q4 2023 came in at $23.6 million, up 28.24% year-over-year; the trailing twelve-month figure through Dec 2023 was $23.6 million (up 28.24% YoY), and the FY2023 annual result was $23.6 million, up 28.24% from the prior year.
• Accumulated Depreciation grew to $23.6 million in Q4 2023 per RLAY's latest filing, from $18.4 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $23.6 million in Q4 2023 and troughed at $7.0 million in Q4 2019.
• A 5-year average of $14.8 million and a median of $14.4 million in 2021 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2020 and 2022: Accumulated Depreciation jumped 50.84% in 2020, then advanced 27.99% in 2022.
• A 5-year view of Accumulated Depreciation shows it stood at $7.0 million in 2019, then surged by 50.84% to $10.5 million in 2020, then soared by 36.44% to $14.4 million in 2021, then increased by 27.99% to $18.4 million in 2022, then gained by 28.24% to $23.6 million in 2023.
• Business Quant data shows RLAY's Accumulated Depreciation at $23.6 million in Q4 2023, $18.4 million in Q4 2022, and $14.4 million in Q4 2021.